The Global Electronic Drug Delivery Systems Market accounted for over US$ 7.6 billion in 2019. It is anticipated to grow at a CAGR of 8.5% from 2020 to 2030.
The success of the therapy and improvements in the condition of patients are dependent on the formulation of dosage form and the exact delivery of the drug to the desired organ. Electronic Drug Delivery Systems (EDDS) is an important innovation in the field of drug delivery systems as it combines controlled drug release, patient monitoring, and real-time wireless communication. It comprises of medical devices, which are used to infuse drugs, growth hormones, and medicines of the desired quantity in patients. These systems enable patients to administer the therapy and make patients independent of caregivers, drug regimens, and medical professionals, thus reducing the overall healthcare expenditure.
Top Players:
Some of the prominent players in the global electronic drug delivery systems market include Merck KGaA, Medtronic, F. Hoffmann-La Roche Ltd, United Therapeutics Corporation, Insulet Corporation., Bayer AG, Novo Nordisk A/S, Amgen Inc., Companion Medical, Tandem Diabetes Care, Inc., and others.
No comments:
Post a Comment